Nervous Disorder TRIZ Cases

A theacrine-caffeine composition sustains energy and focus while reducing anxiety, tolerance, and inflammation markers.

BTK inhibition with ibrutinib addresses cocaine relapse, seizures, and neurotoxicity where behavioral treatment alone falls short.

Fluorinated glucosamine and xylose derivatives inhibit CSPG biosynthesis to support neural cell migration and remyelination in MS.

Targeting plasma cells with cytotoxic agents can shorten CFS symptom relief time while B-cell depletion supports longer-lasting suppression.

An AAV vector co-expresses TH, GCH1, and AADC to fit packaging limits while boosting neuronal transduction and dopamine synthesis.

Moisture-sensitive peptide amide is stabilized for oral tablets using cellulose-silica and starch excipients to limit impurities and preserve absorption.

A modified TAT-FXN fusion polypeptide stays soluble at physiological pH, enabling high-concentration subcutaneous dosing for Friedreich's Ataxia.

SSEA-3-positive Muse cells target impaired brain sites to protect neurons, promote vascular repair, and slow vascular dementia progression.

Small molecules bind RNA structures to modulate splicing while improving oral exposure and blood-brain barrier penetration for neurological disease treatment.

A 5HT3 antagonist such as ondansetron reduces pramipexole GI side effects, enabling higher antidepressant doses with better tolerability.

Monoclonal antibodies bind PCSK9 near catalytic-domain residues to block LDLR interaction, preserve LDLR availability, and lower serum cholesterol.

Selective antibodies bind pathological Tau forms to reduce intraneuronal aggregates while preserving normal Tau function and axonal transport.

eIF2B activator compounds restore translation during ISR signaling, helping treat diseases linked to impaired eIF2B function.

Selective BKCa and SK channel agonists target channel dysfunction to relieve cognitive, behavioral, and sensory hyperexcitability symptoms.

Biodegradable semaglutide microspheres suppress initial burst while sustaining release, reducing injection pain and inflammatory reactions.

Dimethyltryptamine derivatives use nitrate ester groups to deliver nitric oxide in vivo with more targeted release and fewer side effects.

Pyrazole derivatives block SARM1 catalytic activity to preserve NAD+ and help prevent axonal degeneration in neurodegenerative disease.

IgG4 monitoring guides natalizumab dose and interval changes to stabilize exposure and reduce serious infection risk.

Co-expressing AADC, GBA1, and neurotrophic factors in one rAAV vector helps restore dopamine, clear alpha-synuclein, and protect neurons.

Targeted amino substitution on psilocybin reduces panic, paranoia, and psychotic side effects while preserving therapeutic receptor activity.

Defined RXR, RAR, and dual agonist structures narrow compound screening complexity while preserving therapeutic activity against dementia and leukemia.

Combining rifampicin with resveratrol inhibits protein oligomers, improves cognition, and supports longer neurodegenerative treatment with fewer side effects.

A defined serum-free DNT culture removes animal-derived components and anti-CD3 while enabling scalable Tscm- and Tcm-rich expansion.

A soluble Suzuki intermediate and revised deprotection route raise pyrimidinyl bipyridine purity and yield without silica gel.

Combining a proteasome inhibitor with a formula I compound improves efficacy against drug-resistant cancers such as myeloma and TNBC.

By binding oxidized LDL into excretable complexes, sDSS1 therapy helps reduce plaque formation and slow atherosclerosis progression.

Amino acid coupling improves ketone bioavailability and sustained absorption while avoiding the mineral overload of beta-hydroxybutyrate salts.

Isolated mitochondria delivered by injection or vascular infusion help treat ischemia, improve mitochondrial function, and limit chemotherapy cardiotoxicity.

Selective epiregulin neutralization blocks EGFR pain signaling to improve chronic pain relief with fewer side effects and lower immunogenicity.

High-affinity anti-TDP-43 antibodies detect aggregated and physiological forms while blocking spread and promoting aggregate clearance.

Fused benzazepine derivatives reduce liver metabolism and harmful metabolites while preserving selective V2 receptor antagonism and drug action.

Ex vivo stretching aligns astrocyte bundles in a permissive matrix to support neuronal migration and axon regeneration after CNS injury.

A decellularized matrix conduit seeded with NCSC or SCP cells promotes peripheral nerve regeneration without donor-site morbidity.

Localized release of FK506 from a polydioxanone biomaterial provides sustained chemical cues that improve axonal regeneration after nerve injury.

Co-administering a CYP2D6 inhibitor with tasipimidine reduces clearance variability, prolongs half-life, and stabilizes plasma levels.

CRISPR/Cas9 truncates the APP C-terminus to disrupt APP-BACE-1 interaction and reduce amyloid beta production in Alzheimer's models.

A dual immediate- and modified-release 4-((L-valyl)oxy)butanoic acid formulation balances rapid onset with sustained plasma levels and fewer doses.

PEG-lipid shielding helps rHDL nanoparticles evade immune clearance while preserving blood-brain barrier transport for neurodegenerative therapy.

AAV-delivered astrocyte-specific MAGL shRNA crosses the blood-brain barrier to reduce neuroinflammation and improve memory in AD models.

An alkaline pH oral film keeps Montelukast soluble in the stomach, improving absorption consistency and brain delivery for neuroinflammation treatment.

Carboxylic acid indanyl compounds improve S1P5 binding specificity and modulation efficacy for targeted neurodegenerative disease treatment.

A covalent-warhead trifunctional radiopharmaceutical boosts tumor uptake and retention while limiting non-target organ exposure.

Targeted steroid substitutions improve GABA A receptor modulation to treat CNS disorders while addressing efficacy and side-effect limits.

High-load biodegradable microspheres suppress initial burst while extending cagrilintide release and reducing injection-site pain.

Acid-oxidized carbon dots gain blood-brain barrier permeation, bone binding, and fibrillation inhibition for diagnostic and drug delivery use.

Framework-region humanization preserves TRBV9-specific binding while improving antibody affinity and solubility for pathogenic T-cell targeting.

Multi-frequency electrical sensing detects liquid at the nebulizer membrane more reliably, preventing dry running, device damage, and wasted power.

Combining mirodenafil with CORT-108297 targets both amyloid-beta production and clearance to protect nerve cells in dementia treatment.

Targeting TLR2 blockade, this case shows how an anti-TLR2 antibody reduces MSA markers, lowers inflammasomes, and supports neurofibril recovery.

A CNCM I-3690 probiotic composition reduces anxiety, cortisol, and perceived stress within a feasible 1-4 week oral regimen.